Search Results
Dec 21, 2025, 20:00 ET Fosun International Honored with TVB's Highest Accolade, "Outstanding ESG Award"
developed by its Health segment have widely benefited cancer patients. Among them, HANSIZHUANG, an innovative anti-PD-1 monoclonal antibody independently developed by Fosun, is the world's first anti-PD-1 monoclonal antibody approved for the first-line treatment of small cell lung cancer (SCLC). To date, it has
More news about: Fosun
Dec 19, 2025, 11:23 ET Presidential Executive Order Validates DeFloria's Strategy in Pharmaceutical Cannabinoid Drug Development
achieved:A cleared botancial IND application and "Study May Proceed" letter from the FDA;Completion of a Phase 1 PK/PD clinical trial, demonstrating safety and a well-tolerated dosing profile; andFDA authorization to initiate a Phase 2 clinical program evaluating
More news about: Charlotte's Web Holdings, Inc.
Dec 18, 2025, 21:59 ET Kanazawa University research: a new strategy for immune tolerance
efficiently induced the differentiation and expansion of Foxp3⁺ Tregs. These induced Tregs expressed high levels of suppressive molecules such as CTLA-4, PD-L1, and LAG-3, and potently inhibited the proliferation of other T cells in a dose-dependent manner, demonstrating robust suppressive function.
More news about: Kanazawa University
Dec 18, 2025, 09:13 ET VIA Labs Expands Connectivity Portfolio with New Line of Industrial-Grade USB Hub Controllers
serial interfaces, and systems integration to create a rich product portfolio that includes USB Host, Hub, and Device controllers in addition to USB PD controllers. VLI has demonstrated technology and industry leadership through Standards Development and bringing newly developed USB Technologies to market.
More news about: VIA Labs, Inc.
Dec 18, 2025, 06:45 ET Canada Nickel Announces Initial Resources at Midlothian and Bannockburn Projects
on the range of grade and ratio of sulphur to nickel, calculated recovery averages 39% for Ni, 6% for Co, 56% for Fe and 25% for Cr, 32% for Pd and 12% for Pd.Grade estimation was validated by comparison of input and output statistics (Nearest Neighbour and Inverse Distance Squared methods),
More news about: Canada Nickel Company Inc.
Dec 17, 2025, 07:00 ET Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
Rilvegostomig:AstraZeneca is developing rilvegostomig, a first-in-class dual-checkpoint bispecific that delivers co-ordinated PD-1 and TIGIT blockade on the same immune effector cell, restoring antitumor immune activity and supporting the potential for durable, long-term outcomes.
More news about: Compugen Ltd.
Dec 17, 2025, 06:45 ET PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
countries around the world. PADCEV is also approved as a single agent for the treatment of adult patients with la/mUC who have previously received a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy or are ineligible for cisplatin-containing chemotherapy and have previously received one or more
More news about: Astellas Pharma Inc.
Dec 16, 2025, 20:00 ET Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma
preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor).Antengene has also developed
More news about: Antengene Corporation Limited
Dec 16, 2025, 17:00 ET Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
first quarter of 2026. This trial is recruiting patients who have not received prior systemic therapy for unresectable or metastatic HNSCC and have tumor PD-L1 CPS expression equal to or greater than 20. Patients are randomized one to one to either INBRX-106 in combination with Keytruda or Keytruda. The primary
More news about: Inhibrx Biosciences, Inc.
Dec 16, 2025, 13:17 ET Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
positive clinical progress in its ongoing DURIPANC clinical trial combining Ampligen and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi for metastatic pancreatic cancer. The company reported Q3 2025 research and development expenses of approximately
More news about: USA News Group
Dec 16, 2025, 13:02 ET Michael Baker International Selected by U.S. Army to Develop NG9-1-1 GIS and Addressing Data at 54 Army Installations
DATAMARK Technologies, has been selected by the U.S. Army's Product Director Base Emergency Communications System (PD BECS), Program Executive Office for Command, Control, Communications, and Network (PEO C3N) to support Public Safety Answering Point (PSAP) modernization
More news about: Michael Baker International
Dec 16, 2025, 05:59 ET Breakthrough Progress: METiS TechBio Publishes Consecutive Research Findings in Nature Communications and the Journal for ImmunoTherapy of Cancer
reported that patients treated with PD-1 inhibitors nearly doubled their three-year survival if they had also received an mRNA COVID-19 vaccine—a finding that strongly aligns with our observations for MTS-107. These results highlight how mRNA platforms can synergize with PD-1 blockade and signal a new chapter
More news about: METiS TechBio
Dec 15, 2025, 07:00 ET RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
CD5⁺) counts by 50% compared to controls and lowered CD3+, CD4+ and CD8+ T cell counts compared to controls with lowered PD1 expression (CD8+)4Data shows opaganib's venetoclax combination potential in CLL; builds on multiple
More news about: RedHill Biopharma Ltd.
Dec 15, 2025, 05:00 ET Minghui Pharmaceutical Announces FDA clearance of IND to Initiate Global Phase Ⅲ Trials of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Thyroid Eye Disease
with two complementary growth engines: a robust clinical oncology portfolio built on its proprietary antibody-drug conjugate (ADC) platform and a novel PD-1/VEGF bispecific antibody (bsAb), and late-stage autoimmune assets advancing toward commercialization. The Company's pipeline includes 13 candidates,
More news about: Minghui Pharmaceutical
Dec 12, 2025, 08:45 ET Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025
frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with PD-1 checkpoint inhibitors including KEYTRUDA® and OPDIVO® by depleting myeloid derived suppressor cells (MDSCs), which represents
More news about: Actinium Pharmaceuticals, Inc.
Dec 12, 2025, 07:00 ET Marengo to Present Initial Results from Invikafusp Alfa and TRODELVY® Combination Study, STARt-002, at the 2025 San Antonio Breast Cancer Symposium
metastatic breast cancer at select cancer centers across North America."Invikafusp has already demonstrated promising single-agent activity in PD-1-resistant tumors, including breast cancer," said Kevin Chin, M.D., Chief Medical Officer of Marengo Therapeutics. "These initial findings further support
More news about: Marengo Therapeutics
Dec 12, 2025, 05:33 ET Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion
EU, a/k/a POBEVCY® in China. In addition, the company has more than 20 promising candidates in clinical trials, focusing on immuno-oncology in the post-PD-1 era and targeted therapies such as antibody-drug conjugates (ADCs). For more information, please visit www.bio-thera.com/en/
More news about: Bio-Thera Solutions, Ltd
Dec 11, 2025, 21:31 ET Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab
treatment in many gastric cancer patients with high PD-L1 expression (CPS >5), its efficacy is markedly limited in gastric cancer patients with low PD-L1 expression (CPS <5) or negative PD-L1 expression (CPS <1). These low and negative PD-L1 patients constitute well more than half of the total
More news about: Akeso, Inc.
Dec 11, 2025, 11:04 ET SAS Hackathon 2025 champions spark innovation, improve lives
Hong Kong]. Parkinson's disease (PD) affects more than 10 million people globally, and that number is expected to double by 2040. Using SAS Viya, SAS Model Studio and Python tools, this team developed Neuro Drift, an AI-powered solution that monitors subtle changes in PD symptoms using wearables, smartphones
More news about: SAS
Dec 11, 2025, 08:00 ET HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025
to how PD-1/PD-L1 inhibitors function as foundational T-cell backbones in oncology. HCB101 is designed for broad combinability across established and emerging treatment modalities, including:ChemotherapyAntibody-drug conjugates (ADCs)Anti-PD-1/anti-PD-L1 checkpoint
More news about: HanchorBio Inc.
Dec 11, 2025, 07:47 ET Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
Keynote-522, the standard neoadjuvant treatment for TNBC includes systemic chemotherapy (anthracyclines, cyclophosphamide, paclitaxel, carboplatin) and the anti-PD-1 monoclonal antibody pembrolizumab. pCR rates are 65%, with rates generally lower in the larger-sized tumors or with lymph node metastasis. The toxicity
More news about: Intensity Therapeutics Inc.
Dec 11, 2025, 07:00 ET Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress
cemiplimab. The early responses we are observing in these difficult-to-treat tumors—despite patients having received prior therapies, including other PD-1/PD-L1 agents—are particularly encouraging. We also have patients remaining on therapy beyond six months, suggesting the potential for durable disease
More news about: Biohaven Ltd.
Dec 11, 2025, 00:50 ET 新橋生物公佈 Ragistomig 1期劑量拓展研究數據：療效可比，安全性顯著提升
Ragistomig 是一種 4-1BB X PD-L1 雙特異性抗體，旨在治療使用檢查點抑制劑後復發或難治的晚期或轉移性實體瘤患者。作為癌症治療的支柱，檢查點抑制劑市場規模達數十億美元，但廣泛存在的耐藥性限制了其療效。研究目標已達成：對於既往使用過抗PD-(L)1等免疫療法後難治或復發的患者，新的每6週一次（Q6W） 延長給藥間隔方案不僅展現出了令人鼓舞的抗腫瘤療效和免疫學數據，相較於此前每2週一次（Q2W）的方案，安全性也顯著改善。本次發佈的海報展示了包含CD8+ 細胞增殖和記憶 T 細胞活化在內的積極免疫學數據。
More news about: 新橋生物
Dec 10, 2025, 22:19 ET ELFBAR e LOST MARY anunciam avanços históricos em P&D e novos protocolos de segurança para 2025
content:https://www.prnewswire.com/br/comunicados-para-a-imprensa/elfbar-e-lost-mary-anunciam-avancos-historicos-em-pd-e-novos-protocolos-de-seguranca-para-2025-302638700.htmlFONTE
More news about: ELFBAR; LOST MARY
Dec 10, 2025, 20:53 ET Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025
("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/VEGF bispecific antibody) combined with chemotherapy as a first-line treatment for locally advanced unresectable or metastatic triple-negative breast
More news about: Akeso, Inc.